Keeping Our Cool: Developing a Cold-Chain to Further Treatment Access
The Max Foundation is always seeking new ways to improve our programs and better serve people facing cancer in low- and middle-income countries. As Supply Chain & Logistics Manager, my focus is on improving our supply chain (i.e., how we move medicine from just three warehouses to 98 different hospitals and clinics around the world).
Improving a supply chain can mean different things to different people. It might mean performing quality audits, refining demand forecasting, or reducing shipping costs. It might also mean shipping a new kind of product you’ve never shipped before. That’s just the kind of improvement The Max Foundation is making right now.
Shipping and logistics is one of four pillars in our Max Access Solutions.
Patients First
The Max Foundation facilitates cancer treatment access in low- and middle-income countries around the world. Of the 15,000+ patients we support, most respond well to targeted therapy in tablet form. However, some require intravenous therapies for successful treatment, and the implications for the supply chain are huge. As a patient-centered organization, we aim to provide any therapy needed whenever possible. Recently, that’s meant adding “cold-chain” products to our supply chain.
What are “cold-chain” products?
A “cold-chain” product must remain within a specific temperature range at all times. On days- or weeks-long international shipments, it’s especially challenging (and expensive) to keep medicine at a constant temperature. There can be weather shifts, customs delays, and on-site storage issues just to name a few common circumstances.
Despite the inherent challenges, adding cold-chain capability is well worth the effort for the patients we support. By doing so, The Max Foundation will be able to better meet the needs of patients who are unresponsive to tablet therapies.
Start a Cold-Chain
The Patan Academy of Health Sciences in Nepal
We are so proud to share that in September of 2018, The Max Foundation successfully delivered its first cold-chain product. Dr. Kayastha Gyan at the Patan Academy of Health Sciences in Nepal received a shipment of Torisel, an intravenous therapy used to treat kidney cancer.
The shipment began its journey at our distributor’s warehouse in Charlotte, North Carolina, traveled 8,012 miles, cleared customs in Nepal, and arrived at the Patan Academy of Health Sciences just over four days later. During its four-day journey, the package remained within a constant temperature range of between two and eight degrees Celsius (that’s 35.6 to 46.4 Fahrenheit). Because we were able to make this shipment, a patient in Nepal gained access to potentially lifesaving treatment.
Partners Make it Possible
We didn’t make this progress alone. Our logistics partner Tanner Pharma Group provided expertise and guided the process every step of the way. Thanks to our innovative partnership, we can continue to expand our portfolio of cancer treatments. And we can continue bringing dignity and hope to people facing cancer all over the world.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Related Articles
The GIPAP Program Detailed in the ASCO Journal of Global Oncology
Last week ASCO launched the inaugural issue of the Journal of Global Oncology. This new open access, online journal focuses exclusively on cancer research, treatment, and the delivery of care in middle and low resource countries.
Among the first seven articles, published on September 23rd, are original research, commentaries, and review articles, including a special article looking at the Glivec International Patient Assistance Program (GIPAP), authored by our CEO Pat Garcia-Gonzalez, MS, and others.
Road to Laos: Joy as first MAS Shipment of Medication Arrives!
After weeks of anxious anticipation, February 10, 2023, was a day of incredible joy for us as the first shipment of medication successfully arrived in our partner hospital in Laos and soon into the welcoming hands of the patients – specifically young Ammonlath! Journey kicks off! Our journey started a year ago, in Jan 2022,….
Interview with Pat Garcia-Gonzalez with GlobalWA
For World Cancer Day, GlobalWA interviewed Max CEO Pat Garcia-Gonzalez to hear about the many lessons she has learned in this work, and how both cancer treatment and patients’ access to treatment globally has changed.
The Max Foundation uses cookies to improve your experience on our site. Please read our Privacy Policy for more information.